Last reviewed · How we verify
Hizentra
At a glance
| Generic name | Hizentra |
|---|---|
| Also known as | IgPro20, Immune Globulin Subcutaneous (Human), 20% Liquid, subcutaneous gammaglobulin therapy |
| Sponsor | CSL Behring |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia (PHASE2)
- A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
- IVIG vs SCIG in CIDP (PHASE1)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) (PHASE3)
- Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS (PHASE3)
- At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill
- Subcutaneous Immunoglobulin for Myasthenia Gravis (PHASE2)
- Usage of Spirometry in Managing IgG Therapy in CVID with Airway Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |